GUOBANG PHARMA was founded in 1996 and went public in 2021 (stock code: 605507.SH). It is a global-oriented, multi-product pharmaceutical manufacturing company with the ability to produce a variety of key intermediates in-house. It is among the top 100 pharmaceutical companies in China. The company focuses on life and health active substances, specializing in human medicine, animal health care, plant protection, functional nutrition, rehabilitation and health care, and other fields. It is deeply committed to the development of its main functional areas and aims to become a leading multi-product enterprise in the global pharmaceutical manufacturing industry chain. 

     The company has modern production bases in two national-level industrial parks in Shangyu, Zhejiang and Weifang, Shandong. Its products have obtained international market certifications in line with the standards of the US FDA, the EU GMP, the Japanese PMDA, and the Brazilian ANVISA. The company adheres to a dual-driven strategy both domestically and internationally, and has established a global sales network. Its products are sold to 117 countries and regions across six continents, with over 5,000 supply and sales partners, serving nearly 7 billion people. Currently, the company has over 2,500 mu of operating land, more than 4,300 employees, and has been granted 220 authorized patents. Its total assets amount to nearly 11 billion yuan, with an expected annual revenue of 6.011 billion yuan and a net profit attributable to the parent company of 821 million yuan in 2025. 

      In the future, the company will continue to uphold the industry tenet of "sharing the beauty of science, nature and life", pursue scientific innovation, strive to become a leading enterprise in product variety, and be committed to building a "world-class supporting factory for health and active products", making medicines accessible to those who cannot afford them and available to those who cannot obtain them, and serving the health of more people around the world.